Abstract: Objective To investigate the clinical effect of magnesium isoglycyrrhizinate combined with reduced glutathione in the treatment of patients with chemotherapeutic drug-induced liver injury. Methods 80 patients with chemotherapeutics-induced liver injury were randomly divided into two groups. Patients in combination treatment group（n=45） were treated intravenously with magnesium isoglycyrrhizinate combined with reduced glutathione for 2 weeks,and the patients in control group（n=35） were treated with reduced glutathione alone. The serum levels of ALT and AST were observed. Results At the end of 2 week treatment,the serum levels of ALT and AST in control group were（88±45） U/L and（98±53） U/L,significantly decreased as compared with those pre-treatment [（130±60） U/L,and （138±70） U/L,P<0.05];serum levels of ALT and AST in combination treatment group were（55±38） U/L and（56±43） U/L,significantly decreased as compared with those pre-treatment [（125±47） U/L,and （158±68） U/L,P<0.05] in this group and in the controls （P<0.05）;In patients aged younger than 60 years,the serum levels of ALT and AST in 27 patients receiving combination treatment after treatment were （45±23） U/L and（40±35） U/L,and those in 20 patients in control decreased to （60±30） U/L and（65±34） U/L];while in patients older than 60 years,the serum levels of ALT[（103±45） U/L] and AST [（99±50）U/L] after combination treatment in 18 patients were significantly lower than those in 15 controls[（145±80） U/L and（151±65） U/L,P<0.05]. Conclusion Magnesium isoglycyrrhizinate combined with reduced glutathione is effective in the treatment of patients with chemotherapeutic drug-induced liver injury.

Key words: Drug-induced liver injury, Chemotherapy, Magnesium isoglycyrrhizinate, Reduced glutathione, Therapy